Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1967 1
1968 1
1974 1
1975 6
1979 2
1980 2
1981 3
1982 9
1983 6
1984 9
1985 7
1986 10
1987 6
1988 9
1989 10
1990 12
1991 7
1992 11
1993 9
1994 19
1995 15
1996 14
1997 24
1998 23
1999 25
2000 32
2001 25
2002 47
2003 85
2004 96
2005 115
2006 162
2007 195
2008 214
2009 269
2010 318
2011 409
2012 473
2013 546
2014 650
2015 701
2016 754
2017 877
2018 989
2019 1185
2020 1407
2021 1708
2022 1994
2023 2019
2024 2195
2025 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,903 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Among authors: bai y. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: bai y. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Pembrolizumab in HER2-Positive Gastric Cancer.
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, Yañez P, Wyrwicz LS, Shen L, Ostapenko Y, Bilici M, Chung HC, Shitara K, Qin S, Van Cutsem E, Tabernero J, Luo S, Mahave M, Tang Y, Lowery M, Monteiro MMF, Xu L, Shih CS, Sharan KP, Bhagia P, Rha SY. Janjigian YY, et al. Among authors: bai y. N Engl J Med. 2024 Oct 10;391(14):1360-1362. doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14. N Engl J Med. 2024. PMID: 39282917 Free PMC article. Clinical Trial. No abstract available.
Spatiotemporal modeling of molecular holograms.
Qiu X, Zhu DY, Lu Y, Yao J, Jing Z, Min KH, Cheng M, Pan H, Zuo L, King S, Fang Q, Zheng H, Wang M, Wang S, Zhang Q, Yu S, Liao S, Liu C, Wu X, Lai Y, Hao S, Zhang Z, Wu L, Zhang Y, Li M, Tu Z, Lin J, Yang Z, Li Y, Gu Y, Ellison D, Chen A, Liu L, Weissman JS, Ma J, Xu X, Liu S, Bai Y. Qiu X, et al. Among authors: bai y. Cell. 2024 Nov 11:S0092-8674(24)01159-0. doi: 10.1016/j.cell.2024.10.011. Online ahead of print. Cell. 2024. PMID: 39532097 Free article.
Hypoxia and ferroptosis.
Liu XQ, Shi MZ, Bai YT, Su XL, Liu YM, Wu JC, Chen LR. Liu XQ, et al. Among authors: bai yt. Cell Signal. 2024 Oct;122:111328. doi: 10.1016/j.cellsig.2024.111328. Epub 2024 Jul 31. Cell Signal. 2024. PMID: 39094672 Free article. Review.
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, Xu J, Zhang H, Chen J, Yuan Y, Liu T, Yang L, Zhong H, Chen D, Shen L, Hao C, Fu D, Cheng Y, Yang J, Wang Q, Qin B, Pan H, Zhang J, Bai X, Zheng Q. Qin S, et al. Among authors: bai y. J Clin Oncol. 2023 Nov 20;41(33):5163-5173. doi: 10.1200/JCO.22.02630. Epub 2023 Aug 30. J Clin Oncol. 2023. PMID: 37647576 Free PMC article. Clinical Trial.
15,903 results
You have reached the last available page of results. Please see the User Guide for more information.